Despite these constraints, the investigators concluded that the results reinforce current perinatal HIV treatment ...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...
Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced ...
JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four ...
Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology -HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals ...
Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...
Clinical Trials Arena on MSN
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
There are currently no approved disease-modifying therapies for MPS IIIA.
A new study suggests that babies are able to distinguish between the different objects they see around them at 2 months old, ...
Decades after a landmark study showed the lasting health effects of such trauma, researchers are finding ways to guard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results